NCT00074048View on ClinicalTrials.gov

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

July 31, 2008

Conditions
Leukemia
Interventions
DRUG

BL22

Dosing via IV on Days 1,3, and 5.

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00074048 - BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia | Biotech Hunter | Biotech Hunter